Broadly, NSCLC correlates with gene alterations that have further led to major targeted therapy strategies, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and B-Raf proto-oncogene (BRAF) [151–153]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.